[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
中国进展期乳腺癌共识指南2020 (CABC3) [J]. 癌症进展, 2020, 18(19): 1945-1964.
|
[3]
|
Huang, E.H., Tucker, S.L., Strom, E.A., et al. (2004) Postmastectomy Radiation Improves Lo-cal-Regional Control and Survival for Selected Patients with Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy and Mastectomy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical On-cology, 22, 4691-4699.
https://doi.org/10.1200/JCO.2004.11.129
|
[4]
|
Clarke, M., Collins, R., Darby, S., et al. (2005) Effects of Radio-therapy and of Differences in the Extent of Surgery for Early Breast Cancer on Local Recurrence and 15-Year Survival: An Overview of the Randomised Trials. The Lancet (London, England), 366, 2087-2106. https://doi.org/10.1016/S0140-6736(05)67887-7
|
[5]
|
Sjöström, M., Fyles, A., Liu, F.F., et al. (2023) Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 41, 1533-1540. https://doi.org/10.1200/JCO.22.00655
|
[6]
|
Wang, S.L., Fang, H., Song, Y.W., et al. (2019) Hypofractionated versus Conventional Fractionated Postmastectomy Radiotherapy for Patients with High-Risk Breast Cancer: A Random-ised, Non-Inferiority, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 352-360. https://doi.org/10.1016/S1470-2045(18)30813-1
|
[7]
|
Fisher, B., Anderson, S., Bryant, J., et al. (2002) Twen-ty-Year Follow-Up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer. The New England Journal of Medicine, 347, 1233-1241. https://doi.org/10.1056/NEJMoa022152
|
[8]
|
Li, C., Wang, J., Mo, M., et al. (2021) Outcomes in Patients with pT3N0M0 Breast Cancer with and without Postmastectomy Radiotherapy. Cancer Management and Research, 13, 3889-3899. https://doi.org/10.2147/CMAR.S309224
|
[9]
|
Mccormick, B., Winter, K.A., Woodward, W., et al. (2021) Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma in Situ: Long-Term Report from NRG Oncology/RTOG 9804. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 39, 3574-3582.
|
[10]
|
Ma, J.C., Zhong, X.R., Luo, T., et al. (2021) The Effect of Postmastectomy Radiotherapy on Breast Cancer Patients after Neoadjuvant Chemotherapy by Molecular Subtype. Annals of Surgical Oncology, 28, 5084-5095.
https://doi.org/10.1245/s10434-020-09523-1
|
[11]
|
Wang, X., Zhang, L., Zhang, X., et al. (2021) Impact of Clini-cal-Pathological Factors on Locoregional Recurrence in Mastectomy Patients with T1-2N1 Breast Cancer: Who Can Omit Adjuvant Radiotherapy? Breast Cancer Research and Treatment, 190, 277-286. https://doi.org/10.1007/s10549-021-06378-2
|
[12]
|
Hughes, K.S., Schnaper, L.A., Bellon, J.R., et al. (2013) Lum-pectomy plus Tamoxifen with or without Irradiation in Women Age 70 Years or Older with Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. Journal of Clinical Oncology: Official Journal of the American Society of Clin-ical Oncology, 31, 2382-2387.
https://doi.org/10.1200/JCO.2012.45.2615
|
[13]
|
Kunkler, I.H., Williams, L.J., Jack, W.J.L., et al. (2023) Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. The New England Journal of Medicine, 388, 585-594. https://doi.org/10.1056/NEJMoa2207586
|
[14]
|
Whelan, T.J., Smith, S., Parpia, S., et al. (2023) Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer. The New England Journal of Med-icine, 389, 612-619. https://doi.org/10.1056/NEJMoa2302344
|
[15]
|
Ren, X., Yu, Y., Liu, L., et al. (2023) Axillary Response and Outcome in Breast Cancer Patients after Neoadjuvant Treatment: The Role of Radiotherapy in Reducing Recurrence in ypN0 Patients with Initially cN+ Stage. Frontiers in Oncology, 13, Article ID: 1093155. https://doi.org/10.3389/fonc.2023.1093155
|
[16]
|
Lee, J., Kim, J.Y., Bae, S.J., et al. (2021) The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemo-therapy. Cancers, 13, Article No. 6205.
https://doi.org/10.3390/cancers13246205
|
[17]
|
Dai, Y., Ma, S., Lan, A., et al. (2023) The Impact of Postmastecto-my Radiotherapy on cT1-2N1 Breast Cancer Patients with ypN0 after Neoadjuvant Chemotherapy: A Retrospective Study Based on Real-World Data. Discover Oncology, 14, 2. https://doi.org/10.1007/s12672-022-00609-8
|
[18]
|
De Wild, S.R., De Munck, L., Simons, J.M., et al. (2022) De-Escalation of Radiotherapy after Primary Chemotherapy in cT1-2N1 Breast Cancer (RAPCHEM; BOOG 2010-03): 5-Year Follow-Up Results of a Dutch, Prospective, Registry Study. The Lancet Oncology, 23, 1201-1210. https://doi.org/10.1016/S1470-2045(22)00482-X
|
[19]
|
Gaál, S., Kahán, Z., Paczona, V., et al. (2021) Deep-Inspirational Breath-Hold (DIBH) Technique in Left-Sided Breast Cancer: Various Aspects of Clinical Utility. Radiation Oncology (London, England), 16, Article No. 89.
https://doi.org/10.1186/s13014-021-01816-3
|
[20]
|
Bruzzaniti, V., Abate, A., Pinnarò, P., et al. (2013) Dosimetric and Clinical Advantages of Deep Inspiration Breath- Hold (DIBH) during Radiotherapy of Breast Cancer. Journal of Experimental & Clinical Cancer Research: CR, 32, Article No. 88. https://doi.org/10.1186/1756-9966-32-88
|
[21]
|
Bentzen, S.M., Agrawal, R.K., Aird, E.G., et al. (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: A Randomised Trial. The Lancet Oncology, 9, 331-341. https://doi.org/10.1016/S1470-2045(08)70077-9
|
[22]
|
Bentzen, S.M., Agrawal, R.K., Aird, E.G., et al. (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: A Randomised Trial. The Lancet (London, England), 371, 1098-1107. https://doi.org/10.1016/S0140-6736(08)60348-7
|
[23]
|
Whelan, T.J., Olivotto, I.A., Parulekar, W.R., et al. (2015) Regional Nodal Irradiation in Early-Stage Breast Cancer. The New England Journal of Medicine, 373, 307-316. https://doi.org/10.1056/NEJMoa1415340
|
[24]
|
Poortmans, P.M., Weltens, C., Fortpied, C., et al. (2020) Internal Mammary and Medial Supraclavicular Lymph Node Chain Irradiation in Stage I-III Breast Cancer (EORTC 22922/10925): 15-Year Results of a Randomised, Phase 3 Trial. The Lancet Oncology, 21, 1602-1610. https://doi.org/10.1016/S1470-2045(20)30472-1
|
[25]
|
Thorsen, L.B., Offersen, B.V., Danø, H., et al. (2016) DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncolo-gy, 34, 314-320. https://doi.org/10.1200/JCO.2015.63.6456
|
[26]
|
Kim, Y.B., Byun, H.K., Kim, D.Y., et al. (2022) Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women with Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial. JAMA Oncology, 8, 96-105. https://doi.org/10.1001/jamaoncol.2021.6036
|
[27]
|
Asaoka, M., Narui, K., Suganuma, N., et al. (2019) Clinical and Pathological Predictors of Recurrence in Breast Cancer Patients Achieving Pathological Complete Response to Neoadju-vant Chemotherapy. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 45, 2289-2294. https://doi.org/10.1016/j.ejso.2019.08.001
|
[28]
|
Nguyen, D., Yu, J., Reinhold, W.C., et al. (2020) Association of Independent Prognostic Factors and Treatment Modality with Survival and Recurrence Outcomes in Breast Cancer. JAMA Network Open, 3, e207213.
https://doi.org/10.1001/jamanetworkopen.2020.7213
|
[29]
|
Zhao, X., Tang, Y., Wang, S., et al. (2020) Locoregional Recurrence Patterns in Women with Breast Cancer Who Have Not Undergone Post-Mastectomy Radiotherapy. Radiation Oncology (London, England), 15, Article No. 212.
https://doi.org/10.1186/s13014-020-01637-w
|
[30]
|
Asaga, S., Kinoshita, T., Shiino, S., et al. (2019) Prognostic Factors for Breast Cancer Patients with T1-2 Tumor and 1-3 Positive Axillary Nodes Treated Using Total Mastectomy without Radiotherapy. The Breast Journal, 25, 26-33.
https://doi.org/10.1111/tbj.13148
|
[31]
|
Yamada, A., Hayashi, N., Kumamaru, H., et al. (2022) Prognostic Impact of Postoperative Radiotherapy in Patients with Breast Cancer and With pT1-2 and 1-3 Lymph Node Metastases: A Retro-spective Cohort Study Based on the Japanese Breast Cancer Registry. European Journal of Cancer (Oxford, England: 1990), 172, 31-40.
https://doi.org/10.1016/j.ejca.2022.05.017
|
[32]
|
Stuart-Harris, R., Dahlstrom, J.E., Gupta, R., et al. (2019) Recur-rence in Early Breast Cancer: Analysis of Data from 3765 Australian Women Treated between 1997 and 2015. Breast (Edinburgh, Scotland), 44, 153-159.
https://doi.org/10.1016/j.breast.2019.02.004
|
[33]
|
Chang, J.M., Leung, J.W.T., Moy, L., et al. (2020) Axillary Nodal Evaluation in Breast Cancer: State of the Art. Radiology, 295, 500-515. https://doi.org/10.1148/radiol.2020192534
|
[34]
|
Phung, M.T., Tin Tin, S. and Elwood, J.M. (2020) Prognostic Models for Breast Cancer: A Systematic Review. BMC Cancer, 19, Article No. 230. https://doi.org/10.1186/s12885-019-5442-6
|
[35]
|
Sopik, V., Sun, P. and Narod, S.A. (2019) Predictors of Time to Death after Distant Recurrence in Breast Cancer Patients. Breast Cancer Research and Treatment, 173, 465-474. https://doi.org/10.1007/s10549-018-5002-9
|
[36]
|
Dieci, M.V., Conte, P.P., Bisagni, P.G., et al. (2023) Metastatic Site Patterns by Intrinsic Subtype and HER2DX in Early HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 116, 69-80.
https://doi.org/10.1093/jnci/djad179
|
[37]
|
Cheun, J.H., Kim, H.K., Moon, H.G., et al. (2023) Locoregional Recur-rence Patterns in Patients with Different Molecular Subtypes of Breast Cancer. JAMA Surgery, 158, 841-852. https://doi.org/10.1001/jamasurg.2023.2150
|
[38]
|
Pan, X.B., Chen, R.J., Huang, S.T., et al. (2017) Systematic Re-view and Meta-Analysis of the Efficacy of Breast Conservation Therapy Followed by Radiotherapy in Four Breast Can-cer Subtypes. Oncotarget, 8, 57414-57420.
https://doi.org/10.18632/oncotarget.18205
|
[39]
|
Vihervuori, H., Korpinen, K., Autere, T.A., et al. (2022) Varying Outcomes of Triple-Negative Breast Cancer in Different Age Groups-Prognostic Value of Clinical Features and Prolifer-ation. Breast Cancer Research and Treatment, 196, 471-482. https://doi.org/10.1007/s10549-022-06767-1
|
[40]
|
Hassaine, Y., Jacquet, E., Seigneurin, A., et al. (2022) Evolution of Breast Cancer Incidence in Young Women in a French Registry from 1990 to 2018: Towards a Change in Screening Strategy? Breast Cancer Research: BCR, 24, Article No. 87. https://doi.org/10.1186/s13058-022-01581-5
|
[41]
|
Bouferraa, Y., Haibe, Y., Chedid, A., et al. (2022) The Impact of Young Age (< 40 Years) on the Outcome of a Cohort of Patients with Primary Non-Metastatic Breast Cancer: Analysis of 10-Year Survival of a Prospective Study. BMC Cancer, 22, Article No. 27. https://doi.org/10.1186/s12885-021-09100-z
|
[42]
|
Vila, J., Teshome, M., Tucker, S.L., et al. (2017) Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-Regional Recurrence Following Ne-oadjuvant Chemotherapy for Breast Cancer. Annals of Surgery, 265, 574-580. https://doi.org/10.1097/SLA.0000000000001492
|
[43]
|
Marmé, F., Solbach, C., Michel, L., et al. (2021) Utility of the CPS + EG Scoring System in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy. European Journal of Cancer (Oxford, England: 1990), 153, 203-212.
https://doi.org/10.1016/j.ejca.2021.05.027
|
[44]
|
Xu, L., Duan, X., Zhou, B., et al. (2018) Validation of the CPS + EG and Neo-Bioscore Staging Systems after Preoperative Systemic Therapy for Breast Cancer in a Single Center in Chi-na. Breast (Edinburgh, Scotland), 40, 29-37.
https://doi.org/10.1016/j.breast.2018.03.010
|
[45]
|
Thangarajah, F., Enninga, I., Malter, W., et al. (2017) A Retro-spective Analysis of Ki-67 Index and Its Prognostic Significance in over 800 Primary Breast Cancer Cases. Anticancer Research, 37, 1957-1964.
https://doi.org/10.21873/anticanres.11536
|
[46]
|
Zhu, X., Chen, L., Huang, B., et al. (2020) The Prognostic and Pre-dictive Potential of Ki-67 in Triple-Negative Breast Cancer. Scientific Reports, 10, Article No. 225. https://doi.org/10.1038/s41598-019-57094-3
|
[47]
|
Jing, H., Tang, Y., Wang, Z.Z., et al. (2023) Individualized Clinical Target Volume for Irradiation of the Supraclavicular Region in Breast Cancer Based on Mapping of the Involved Ipsilateral Supraclavicular Lymph Nodes. International Journal of Radiation Oncology, Biology, Physics, 115, 922-932. https://doi.org/10.1016/j.ijrobp.2022.10.030
|
[48]
|
Jing, H., Wang, S.L., Li, J., et al. (2015) Mapping Patterns of Ip-silateral Supraclavicular Nodal Metastases in Breast Cancer: Rethinking the Clinical Target Volume for High-Risk Pa-tients. International Journal of Radiation Oncology, Biology, Physics, 93, 268-276. https://doi.org/10.1016/j.ijrobp.2015.08.022
|
[49]
|
Almahariq, M.F., Maywood, M.J., Levitin, R.B., et al. (2020) Mapping of Metastatic Level I Axillary Lymph Nodes in Patients with Newly Diagnosed Breast Cancer. International Journal of Radiation Oncology, Biology, Physics, 106, 811-820. https://doi.org/10.1016/j.ijrobp.2019.12.010
|
[50]
|
Deselm, C., Yang, T.J., Cahlon, O., et al. (2019) A 3-Dimensional Mapping Analysis of Regional Nodal Recurrences in Breast Cancer. International Journal of Radiation Oncology, Biology, Physics, 103, 583-591.
https://doi.org/10.1016/j.ijrobp.2018.10.021
|
[51]
|
Xu, H.P., Bronsart, E., Costa, É., et al. (2019) Patterns of Lo-coregional Failure in Women with Early-Stage Breast Cancer Treated by Whole Breast Irradiation in the Lateral Isocentric Decubitus Position: Large-Scale Single-Centre Experience. Cancer Radiotherapie: Journal de la Societe Francaise de Radiotherapie Oncologique, 23, 116-124.
https://doi.org/10.1016/j.canrad.2018.08.002
|
[52]
|
弋振营, 申凤乾, 李宁, 等. 乳腺癌改良根治术术后放疗的疗效及预后影响因素分析[J]. 癌症进展, 2021, 19(2): 171-173+193.
|